|
1
|
Astuti N and Maggiolo F: Single-tablet
regimens in HIV therapy. Infect Dis Ther. 3:1–17. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Sarma P, Cassidy R, Corlett S and
Katusiime B: Ageing with HIV: Medicine optimisation challenges and
support needs for older people living with HIV: A systematic
review. Drugs Aging. 40:179–240. 2023.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Panel on Antiretroviral Guidelines for
Adults N. Guidelines for the Use of Antiretroviral Agents in Adults
and Adolescents With HIV How to Cite the Adult and Adolescent
Antiretroviral Guidelines: Panel on Antiretroviral Guidelines for
Adults and Adolescents. Guidelines for the Use of Antiretroviral
Agents in Adults and Adolescents. Available from: https://clinicalinfo.hiv.gov/.
|
|
4
|
EACS European AIDS Clinical Society 1 EACS
Guidelines 12.0. https://www.eacsociety.org/media/guidelines-12.0.pdf.
|
|
5
|
Ramanathan S, Mathias AA, German P and
Kearney BP: Clinical pharmacokinetic and pharmacodynamic profile of
the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet.
50:229–244. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Cottrell ML, Hadzic T and Kashuba ADM:
Clinical pharmacokinetic, pharmacodynamic and Drug-interaction
profile of the integrase inhibitor dolutegravir. Clin
Pharmacokinet. 52:981–994. 2013.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Pham HT and Mesplède T: Bictegravir in a
fixed-dose tablet with emtricitabine and tenofovir alafenamide for
the treatment of HIV infection: Pharmacology and clinical
implications. Expert Opin Pharmacother. 20:385–397. 2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Calcagno A, D'Avolio A and Bonora S:
Pharmacokinetic and pharmacodynamic evaluation of raltegravir and
experience from clinical trials in HIV-positive patients. Expert
Opin Drug Metab Toxicol. 11:1167–1176. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Messiaen P, Wensing AMJ, Fun A, Nijhuis M,
Brusselaers N and Vandekerckhove L: Clinical use of HIV integrase
inhibitors: A systematic review and Meta-analysis. PLoS One.
8(e52562)2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Mbhele N, Chimukangara B and Gordon M:
HIV-1 integrase strand transfer inhibitors: A review of current
drugs, recent advances and drug resistance. Int J Antimicrob
Agents. 57(106343)2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Charpentier C and Descamps D: Resistance
to HIV integrase inhibitors: About R263K and E157Q Mutations.
Viruses. 10(41)2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhao AV, Crutchley RD, Guduru RC, Ton K,
Lam T and Min AC: A clinical review of HIV integrase strand
transfer inhibitors (INSTIs) for the prevention and treatment of
HIV-1 infection. Retrovirology. 19(22)2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Llibre JM, Pulido F, García F, Deltoro MG,
Blanco JL and Delgado R: Genetic barrier to resistance for
dolutegravir [Internet]. Vol. 17, AIDS Reviews. 2015. Available
from: www.permanyer.com.
|
|
14
|
Di Perri G, Calcagno A, Trentalange A and
Bonora S: The clinical pharmacology of integrase inhibitors. Expert
Rev Clin Pharmacol. 12:31–44. 2019.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Spagnuolo V, Castagna A and Lazzarin A:
Bictegravir. Curr Opin HIV AIDS. 13:326–333. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Esser S, Inciarte A, Levy I, D'Arminio
Monforte A, Lambert JS, van Welzen B, Teruya K, Boffito M, Liu CE,
Aydın OA, et al: Combined bictegravir, emtricitabine and tenofovir
alafenamide for treating people with HIV: A plain language summary
of the BICSTaR study up to 1 year. Future Microbiol. 19:1273–1282.
2024.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Esser S, Brunetta J, Inciarte A, Levy I,
D'Arminio Monforte A, Lambert JS, van Welzen B, Teruya K, Boffito
M, Liu CE, et al: Twelve-month effectiveness and safety of
bictegravir/emtricitabine/tenofovir alafenamide in people with HIV:
Real-world insights from BICSTaR cohorts. HIV Med. 25:440–453.
2024.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Januszka J, Drwiega E and Badowski M:
Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is
the hidden potential of this emerging treatment? HIV AIDS (Auckl).
15:705–711. 2023.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Avihingsanon A, Lu H, Leong CL, Hung CC,
Koenig E, Kiertiburanakul S, Lee MP, Supparatpinyo K, Zhang F,
Rahman S, et al: Bictegravir, emtricitabine, and tenofovir
alafenamide versus dolutegravir, emtricitabine, and tenofovir
disoproxil fumarate for initial treatment of HIV-1 and hepatitis B
coinfection (ALLIANCE): A double-blind, multicentre, randomised
controlled, phase 3 non-inferiority trial. Lancet HIV.
10:e640–e652. 2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Mendoza I, Lázaro A, Espinosa A, Sánchez
L, Horta AM and Torralba M: Effectiveness, durability and safety of
dolutegravir and lamivudine versus bictegravir, emtricitabine and
tenofovir alafenamide in a real-world cohort of HIV-infected
adults. PLoS One. 18(e0291480)2023.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Orkin C, DeJesus E, Sax PE, Arribas JR,
Gupta SK, Martorell C, Stephens JL, Stellbrink HJ, Wohl D, Maggiolo
F, et al: Fixed-dose combination bictegravir, emtricitabine, and
tenofovir alafenamide versus dolutegravir-containing regimens for
initial treatment of HIV-1 infection: Week 144 results from two
randomised, double-blind, multicentre, phase 3, Non-inferiority
trials. Lancet HIV. 7:e389–e400. 2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Holt LM, Short WR, Momplaisir F, Hyun E,
McKinney J, Lugo Morales A, Duque A, Druyan B, Ndubizu C, Duthely
L, et al: Bictegravir use during pregnancy: A multicenter
retrospective analysis evaluating HIV viral suppression and
perinatal outcomes. Clin Infect Dis. 79:1258–1261. 2024.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Zhang H, Hindman JT, Lin L, Davis M, Shang
J, Xiao D, Avihingsanon A, Arora P, Palaparthy R, Girish S and
Marathe DD: A study of the pharmacokinetics, safety, and efficacy
of bictegravir/emtricitabine/tenofovir alafenamide in virologically
suppressed pregnant women with HIV. AIDS. 38:F1–F9. 2024.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Mounzer K, Brunet L, Fusco JS, McNicholl
IR, Dunbar M, Sension M, McCurdy LH and Fusco GP: Immune response
to ART initiation in advanced HIV infection. HIV Med. 24:716–726.
2023.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Tseng YT, Yang CJ, Kim YS, Choi JY, Wong
CS, Lee KY, Lee JA, Chang J, Harrison R, Marongiu A, et al:
Twelve-month effectiveness and safety of
bictegravir/emtricitabine/tenofovir alafenamide in treatment-naïve
and treatment-experienced people with HIV: Findings from the Asia
cohort of the BICSTaR study. J Microbiol Immunol Infect.
57:760–770. 2024.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Lake JE and Trevillyan J: Impact of
Integrase inhibitors and tenofovir alafenamide on weight gain in
people with HIV. Curr Opin HIV AIDS. 16:148–151. 2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Eckard AR and McComsey GA: Weight gain and
integrase inhibitors. Curr Opin Infect Dis. 33:10–19.
2020.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Jemal M: A review of
dolutegravir-associated weight gain and secondary metabolic
comorbidities. SAGE Open Med. 12(20503121241260613)2024.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Byonanebye DM, Polizzotto MN, Maltez F,
Rauch A, Grabmeier-Pfistershammer K, Wit F, De Wit S, Castagna A,
d'Arminio Monforte A, Mussini C, et al: Associations between change
in BMI and the risk of hypertension and dyslipidaemia in people
receiving integrase strand-transfer inhibitors, tenofovir
alafenamide, or both compared with other contemporary
antiretroviral regimens: A multicentre, prospective observational
study from the RESPOND consortium cohorts. Lancet HIV.
11:e321–e332. 2024.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Guaraldi G, Milic J, Bacchi E, Carli F,
Menozzi M, Franconi I, Raimondi A, Ciusa G, Masi V, Belli M, et al:
Contribution of integrase inhibitor use, body mass index, physical
activity and caloric intake to weight gain in people living with
HIV. HIV Res Clin Pract. 24:1–6. 2022.PubMed/NCBI
|
|
31
|
Corti N, Menzaghi B, Orofino G,
Guastavigna M, Lagi F, Di Biagio A, Taramasso L, De Socio GV,
Molteni C, Madeddu G, et al: Risk of cardiovascular events in
people with HIV (PWH) treated with integrase strand-transfer
inhibitors: The debate is not over; Results of the SCOLTA study.
Viruses. 16(613)2024.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wood BR and Huhn GD: Excess weight gain
with integrase inhibitors and tenofovir alafenamide: What is the
mechanism and does it matter? Open Forum Infect Dis.
8(ofab542)2021.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Saumoy M, Sanchez-Quesada JL,
Ordoñez-Llanos J and Podzamczer D: Do all integrase strand transfer
inhibitors have the same lipid profile? Review of randomised
controlled trials in naïve and switch scenarios in HIV-infected
patients. J Clin Med. 10(3456)2021.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Pérez-Barragán E, Guevara-Maldonado MF,
Mancilla-Galindo J, Kammar-García A, Ortiz-Hernández A, Mata-Marín
JA and Pérez-Cavazos S: Weight gain after 12 months of switching to
bictegravir/emtricitabine/tenofovir alafenamide in virologically
suppressed HIV patients. AIDS Res Hum Retroviruses. 39:511–517.
2023.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Wohl DA, Koethe JR, Sax PE, McComsey GA,
Kuritzkes DR, Moyle G, Kaplan L, van Wyk J, Campo RE and Cohen C:
Antiretrovirals and weight change: Weighing the evidence. Clin
Infect Dis. 79:999–1005. 2024.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Adachi E, Ikeuchi K, Koga M and
Yotsuyanagi H: Changes in inflammatory biomarkers when switching
from Three-drug regimens to dolutegravir plus lamivudine in people
living with HIV. AIDS Res Hum Retroviruses. 38:881–883.
2022.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Antinori A, Santoro MM, Gagliardini R,
Marchetti G, Mondi A, Cento V, Perno CF and Andreoni M: Two-Drug
Antiretroviral Regimens expert panel. Italian expert panel
consensus statements on two-drug antiretroviral regimens to treat
naïve and virologically suppressed HIV-1 infected patients. New
Microbiol. 42:69–80. 2019.PubMed/NCBI
|
|
38
|
Waters L and Church H: Two drugs regimens
for HIV. Curr Opin Infect Dis. 33:28–33. 2020.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Nasreddine R, Yombi JC, Darcis G, Florence
E, Allard SD, De Scheerder MA, Henrard S, Demeester R, Messiaen P,
Ausselet N, et al: Efficacy, durability, and tolerability of
dolutegravir/lamivudine and dolutegravir/rilpivirine for the
treatment of HIV in a real-world setting in Belgium. HIV Med.
24:267–278. 2023.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Neesgaard B, Pelchen-Matthews A, Ryom L,
Florence E, Peters L, Roen A, Svedhem V, Clarke A, Benfield T,
Mitsura V, et al: Uptake and effectiveness of two-drug compared
with three-drug antiretroviral regimens among HIV-positive
individuals in Europe. AIDS. 33:2013–2024. 2019.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Di Perri G and Bonora S: Clinical
pharmacology of the single tablet regimen
bictegravir/emtricitabine/tenofovir alafenamide in the evolving era
of antiretroviral therapies. New Microbiol. 47:243–250.
2024.PubMed/NCBI
|
|
42
|
Sayyed SK, Quraishi M, Jobby R,
Rameshkumar N, Kayalvizhi N, Krishnan M and Sonawane T: A
computational overview of integrase strand transfer inhibitors
(INSTIs) against emerging and evolving drug-resistant HIV-1
integrase mutants. Arch Microbiol. 205(142)2023.PubMed/NCBI View Article : Google Scholar
|
|
43
|
De Francesco MA, Izzo I, Properzi M,
Gargiulo F, Caccuri F, Quiros-Roldan E, Castelli F, Caruso A and
Focà E: Prevalence of integrase strand transfer inhibitors
resistance mutations in integrase strand transfer Inhibitors-Naive
and -Experienced HIV-1 infected patients: A single center
experience. AIDS Res Hum Retroviruses. 34:570–574. 2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
La Via L, Sangiorgio G, Stefani S, Marino
A, Nunnari G, Cocuzza S, La Mantia I, Cacopardo B, Stracquadanio S,
Spampinato S, et al: The global burden of sepsis and septic shock.
Epidemiologia (Basel). 5:456–478. 2024.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Rolle CP, Nguyen V, Patel K, Cruz D,
DeJesus E and Hinestrosa F: Real-world efficacy and safety of
switching to bictegravir/emtricitabine/tenofovir alafenamide in
older people living with HIV. Medicine. 100(e27330)2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Cohen C: Low-LevelN Viremia in HIV-1
infection: Consequences and implications for switching to a new
regimen. HIV Clin Trials. 10:116–124. 2009.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Crespo-Bermejo C, de Arellano ER,
Lara-Aguilar V, Valle-Millares D, Gómez-Lus ML, Madrid R,
Martín-Carbonero L and Briz V: Persistent low-Level viremia in
persons living with HIV undertreatment: An unresolved status.
Virulence. 12:2919–2931. 2021.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Lara-Aguilar V, Llamas-Adán M,
Brochado-Kith Ó, Crespo-Bermejo C, Grande-García S, Arca-Lafuente
S, de Los Santos I, Prado C, Alía M, Sainz-Pinós C, et al:
Low-level HIV-1 viremia affects T-cell activation and senescence in
long-term treated adults in the INSTI era. J Biomed Sci.
31(80)2024.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Hermans LE, Moorhouse M, Carmona S,
Grobbee DE, Hofstra LM, Richman DD, Tempelman HA, Venter WDF and
Wensing AMJ: Effect of HIV-1 low-level viraemia during
antiretroviral therapy on treatment outcomes in WHO-guided South
African treatment programmes: A multicentre cohort study. Lancet
Infect Dis. 18:188–197. 2018.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Elvstam O, Marrone G, Medstrand P,
Treutiger CJ, Sönnerborg A, Gisslén M and Björkman P: All-Cause
Mortality and serious Non-AIDS events in adults With Low-level
human immunodeficiency virus viremia during combination
antiretroviral therapy: Results from a Swedish nationwide
observational study. Clin Infect Dis. 72:2079–2086. 2021.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Zaçe D, Rindi LV, Compagno M, Colagrossi
L, Santoro MM, Andreoni M, Perno CF and Sarmati L: Low-level HIV
Viremia Consensus Panel. Managing low-level HIV viraemia in
antiretroviral therapy: A systematic review and meta-analysis. Sex
Transm Infect. 100:460–468. 2024.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Jacobs JL, Halvas EK, Tosiano MA and
Mellors JW: Persistent HIV-1 viremia on antiretroviral therapy:
Measurement and mechanisms. Front Microbiol.
10(2383)2019.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Hanners EK, Benitez-Burke J and Badowski
ME: HIV: How to manage low-level viraemia in people living with
HIV. Drugs Context. 11:1–26. 2022.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Esteban-Cantos A, Montejano R,
Pinto-Martínez A, Rodríguez-Centeno J, Pulido F and Arribas JR:
Non-suppressible viraemia during HIV-1 therapy: A challenge for
clinicians. Lancet HIV. 11:e333–e340. 2024.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Shi J, Ying G, Zheng R and Zhang Z:
Clinical significance and management of low-level HIV viremia in
the era of integrase strand transfer inhibitors. HIV Med.
25:361–369. 2024.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Antinori A: Therapy initiation and rapid
start with Bictegravir/Emtricitabine/Tenofovir Alafenamide in PLWH.
Infez Med. 31:277–282. 2023.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Rebeiro PF, Emond B, Rossi C, Bookhart BK,
Shah A, Caron-Lapointe G, Lafeuille MH and Donga P: Incidence of
cardiometabolic outcomes among people living with HIV-1 initiated
on integrase strand transfer inhibitor versus non-integrase strand
transfer inhibitor antiretroviral therapies: A retrospective
analysis of insurance claims in the United States. J Int AIDS Soc.
26(e26123)2023.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Mulindwa F, Kamal H, Castelnuovo B,
Byonanebye DM, Schwarz JM, Bollinger R and Brusselaers N:
Association between integrase strand transfer inhibitor use with
insulin resistance and incident diabetes mellitus in persons living
with HIV: A systematic review and meta-analysis. BMJ Open Diabetes
Res Care. 11(e003136)2023.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Domingo P, Quesada-López T, Villarroya J,
Cairó M, Gutierrez MDM, Mateo MG, Mur I, Corbacho N, Domingo JC,
Villarroya F and Giralt M: Differential effects of dolutegravir,
bictegravir and raltegravir in adipokines and inflammation markers
on human adipocytes. Life Sci. 308(120948)2022.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Clay PG, Yuet WC, Moecklinghoff CH,
Duchesne I, Tronczyński KL, Shah S and Shao D: A meta-analysis
comparing 48-week treatment outcomes of single and multi-tablet
antiretroviral regimens for the treatment of people living with
HIV. AIDS Res Ther. 15(17)2018.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Clay PG, Nag S, Graham CM and Narayanan S:
Meta-Analysis of studies comparing single and Multi-tablet fixed
dose combination HIV treatment regimens. Medicine.
94(e1677)2015.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Sebaaly JC and Kelley D: Single-Tablet
regimens for the treatment of HIV-1 infection. Ann Pharmacother.
51:332–344. 2017.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Sebaaly JC and Kelley D: HIV clinical
updates: New Single-tablet regimens. Ann Pharmacother. 53:82–94.
2019.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Altice F, Evuarherhe O, Shina S, Carter G
and Beaubrun AC: Adherence to HIV treatment regimens: Systematic
literature review and meta-analysis. Patient Prefer Adherence.
13:475–490. 2019.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Cohen A, Seedat J and Sawasawa C:
Dysphagia and pill swallowing in HIV/AIDS in South Africa: Results
of a scoping review. S Afr J Commun Disord. 70:e1–e6.
2023.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Rowe SM, Clary JC, Drummond M, Derrick C,
Sanasi K and Bookstaver PB: Increased viral load in a hospitalized
patient on treatment with crushed
bictegravir/emtricitabine/tenofovir alafenamide: A case report and
review of the literature. Am J Health Syst Pharm. 79:1330–1336.
2022.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Ambrosioni J, Rojas Liévano J, Berrocal L,
Inciarte A, de la Mora L, González-Cordón A, Martínez-Rebollar M,
Laguno M, Torres B, Ugarte A, et al: Real-life experience with
bictegravir/emtricitabine/tenofovir alafenamide in a large
reference clinical centre. J Antimicrob Chemother. 77:1133–1139.
2022.PubMed/NCBI View Article : Google Scholar
|
